Duchenne Muscular Dystrophy Market Size, Share, Growth Analysis, By Therapy(Mutation Suppression, Exon Skipping Approach, Others Therapies), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031

Global Duchenne Muscular Dystrophy Market size was valued at USD 1301.44 million in 2019 and is poised to grow from USD 1362.61 million in 2023 to USD 2060.11 million by 2031, growing at a CAGR of 4.7% in the forecast period (2024-2031).

Duchenne muscular dystrophy is an illness in which muscular weakness happens. Muscle weakness is a defining feature of this hereditary condition. This rare illness primarily affects males. This illness results in mental retardation, respiratory failure, pneumonia, heart failure, muscle weakness, and intellectual incapacity. With the help of this diagnostic care, people with Duchenne muscular dystrophy can receive precise and effective treatment. This sort of diagnostic therapy lessens or manages symptoms but does not provide a cure. In addition to stem cell therapy and gene therapy, medications like steroids are used to treat Duchenne muscular dystrophy and lessen its symptoms.

In the case of DMD, a characteristic of this inherited illness is muscle weakness. Males are the main victims of this rare disease. Mental retardation, pneumonia, heart failure, respiratory failure, muscle weakness, and intellectual disability are all side effects of this condition. People with Duchenne muscular dystrophy can get precise and efficient treatment with the use of this diagnostic care. While not offering a cure, this type of diagnostic therapy lowers or manages symptoms. Drugs like steroids are used to treat Duchenne muscular dystrophy and decrease its symptoms in addition to stem cell therapy and gene therapy.

Global duchenne muscular dystrophy market is anticipated to rise as R&D spending increases to create possible treatments for DMD. For instance, the Muscular Dystrophy Association (MDA), United States, funded $75,000 in research and development to create a DMD treatment. More than 150 hospitals, healthcare facilities, and care facilities in the United States and other nations have received grants from the group.

Additionally, factors like ongoing research into gene and stem cell therapy and exon skipping drugs for DMD treatment are projected to drive global duchenne muscular dystrophy market.

US Duchenne Muscular Dystrophy Market is poised to grow at a sustainable CAGR for the next forecast year.